Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Los Angeles Times
Los Angeles Times
Business
Melody Petersen

Drug to prevent preterm birth pulled from market, years after it was shown ineffective

A pharmaceutical company selling the only drug approved to prevent preterm birth said Tuesday that it would withdraw the medicine from the market.

Covis Pharma said it told the Food and Drug Administration that it would voluntarily withdraw the medicine called Makena, which a study in 2019 showed did not work to extend pregnancies.

"While we stand by Makena's favorable benefit-risk profile, including its efficacy in women at highest risk of preterm birth, we are seeking to voluntarily withdraw the product and work with the FDA to effectuate an orderly wind-down," Raghav Chari, the company's chief innovation officer, said in a statement.

The Times detailed in a February 2022 investigation how Covis and the companies that previously owned the rights to Makena profited by taking a cheap, decades-old medicine with questionable effectiveness and safety and securing FDA authorization for its use.

The FDA had asked Covis, which is owned by private equity firm Apollo Global Management, to pull the drug in 2019. The company refused.

Instead the company, relying on complex federal regulations, asked the FDA to hold a hearing on its request to remove Makena from pharmacies.

At that hearing, not held until October of last year, a committee of experts voted 14-1 that sales of the drug should end because of the lack of scientific proof that it was effective.

At the same time, the drug has a plethora of documented side effects, including depression and hypertension. The FDA says that Makena's possible long-term effects on women and their children are still unknown.

The agency approved Makena 12 years ago despite limited evidence that it worked and objections from an agency scientist.

The FDA must still act on Covis' request to voluntarily withdraw Makena.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.